Victoza vs. Glipizide
See how Victoza and Glipizide compare on approved uses, dosing, side effects, and cost.
Key Takeaways
Victoza is a once-daily injectable GLP-1 drug that also lowers cardiovascular risk, while glipizide is an inexpensive oral pill that only targets blood sugar.
Glipizide carries a real risk of hypoglycemia (low blood sugar), a risk that is much lower with Victoza.
Victoza costs far more than glipizide but adds cardiovascular protection and pediatric approval that glipizide does not have.
Victoza vs. Glipizide Drug Summary
Victoza
Victoza (liraglutide) is a GLP-1 receptor agonist used to improve blood sugar control in adults and children 10 and older with type 2 diabetes. It is also approved to reduce the risk of major cardiovascular events in adults with established heart disease. It is given as a once-daily injection under the skin, with the dose increased gradually over the first few weeks.
Glipizide
Glipizide is a sulfonylurea that helps the pancreas release more insulin to lower blood sugar in adults with type 2 diabetes. It comes as an oral tablet, taken once or twice daily depending on the formulation, and has been used since the 1980s. It works alongside diet and exercise to manage glucose levels.
Victoza vs. Glipizide Side Effects
Victoza
Glipizide
Victoza vs. Glipizide Dosage
Victoza
Glipizide
| STAGE | DOSE | WHEN |
| Starting dose | 0.6 mg once daily | Week 1 |
| Maximum dose | 1.8 mg once daily | Week 3 onward |
| Dose changes | 2 increases | Every week |
| STAGE | DOSE | WHEN |
| Starting dose | 5 mg once daily | At the start |
| Maximum dose | 5-20 mg once daily | If needed |
| Dose changes | 5 increases | As tolerated |
Victoza
| STAGE | DOSE | WHEN |
| Starting dose | 0.6 mg once daily | Week 1 |
| Maximum dose | 1.8 mg once daily | Week 3 onward |
| Dose changes | 2 increases | Every week |
Glipizide
| STAGE | DOSE | WHEN |
| Starting dose | 5 mg once daily | At the start |
| Maximum dose | 5-20 mg once daily | If needed |
| Dose changes | 5 increases | As tolerated |
Victoza vs. Glipizide Indications
Victoza
Victoza is FDA-approved as an add-on to diet and exercise for improving blood sugar in adults and children 10 and older with type 2 diabetes. It is also approved to lower the risk of major cardiovascular events in adults with type 2 diabetes and existing heart disease. It is not approved for type 1 diabetes.
Adjunct to diet and exercise in adults and children 10+
Reduces risk of major cardiovascular events in adults with heart disease
Not approved for type 1 diabetes
Approved for pediatric type 2 diabetes patients
Glipizide
Glipizide is FDA-approved as an add-on to diet and exercise to control blood sugar in adults with type 2 diabetes. It has no cardiovascular risk-reduction indication and is not approved for type 1 diabetes or diabetic ketoacidosis. It remains one of the most widely prescribed generic oral diabetes medications.
Adjunct to diet and exercise in adults with type 2 diabetes
Not approved for type 1 diabetes or diabetic ketoacidosis
Widely used as a first-line generic oral option
Available in immediate-release and extended-release tablets
Victoza vs. Glipizide Pros and Cons
Victoza
Victoza offers glycemic control plus a proven cardiovascular benefit, making it a strong option for patients with type 2 diabetes and heart disease. It requires a daily injection and carries a boxed warning about thyroid tumor risk seen in animal studies. Coverage varies, and the list price is substantially higher than older oral options.
Pros
Only needs to be injected once a day, not multiple pills
FDA-approved to lower cardiovascular risk in patients with heart disease
Approved for use in children as young as 10
Low risk of causing dangerous low blood sugar on its own
Cons
Carries a boxed warning for thyroid C-cell tumor risk
Requires an injection, which some patients dislike
Common gastrointestinal side effects like nausea and vomiting
Roughly $935 to $1,470 per month without insurance, before savings programs
Glipizide
Glipizide is a low-cost, well-established oral option that has been used for decades to lower blood sugar in type 2 diabetes. It carries a higher risk of hypoglycemia than Victoza and has not been shown to reduce cardiovascular risk. It remains inexpensive and widely available as a generic.
Pros
Roughly $10 to $35 per month, one of the least expensive diabetes drugs
Long track record of use dating back to 1984
Simple oral tablet, no injections needed
Widely stocked generic with broad insurance coverage
Cons
Higher risk of hypoglycemia, especially in elderly patients
Sulfonylureas as a class are linked to increased cardiovascular mortality risk
Not proven to reduce cardiovascular events like Victoza is
No effect on appetite or weight, unlike GLP-1 drugs
Common Symptoms and Related Diseases You Can Explore
Explore a range of common symptoms the Doctronic Symptom Checker can help you understand.